Belite Bio, Inc (BLTE)
Automate Your Wheel Strategy on BLTE
With Tiblio's Option Bot, you can configure your own wheel strategy including BLTE - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol BLTE
- Rev/Share 0.0
- Book/Share 4.6361
- PB 13.8521
- Debt/Equity 0.0037
- CurrentRatio 24.3096
- ROIC -0.2733
- MktCap 2090026028.0
- FreeCF/Share 0.0
- PFCF 0.0
- PE -55.8855
- Debt/Assets 0.0035
- DivYield 0
- ROE -0.3082
- Rating C
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 2
- P/B Score 1
- D/E Score 4
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| No ratings available. | |||||||
News
Belite Bio Announces FDA Granting of Breakthrough Therapy Designation for Tinlarebant for the Treatment of Stargardt Disease
Published: May 21, 2025 by: GlobeNewsWire
Sentiment: Neutral
SAN DIEGO, May 21, 2025 (GLOBE NEWSWIRE) -- Belite Bio, Inc. (NASDAQ: BLTE), a clinical-stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for Tinlarebant for the treatment of Stargardt disease (STGD1) based on the previously reported interim data from the ongoing Phase 3 DRAGON trial. There are currently no approved treatments for STGD1.
Read More
Belite Bio: Investors Face Tricky Decision Ahead Of Key STGD1 Study Readout
Published: May 15, 2025 by: Seeking Alpha
Sentiment: Positive
Belite Bio's lead drug, Tinlarebant, shows promise in rare eye diseases, but pivotal data and regulatory approval remain at least 18 months away in my view. The DRAGON study's interim analysis is encouraging, but assumptions of success are risky given the small STGD1 market and lack of robust clinical data. Belite's $2bn valuation appears to price in success for both STGD1 and GA, yet GA efficacy data is lacking and competition is fierce.
Read More
Belite Bio, Inc to Present at the dbVIC - Deutsche Bank ADR Virtual Investor Conference May 15th
Published: May 12, 2025 by: GlobeNewsWire
Sentiment: Neutral
Company invites individual and institutional investors, as well as advisors and analysts, to attend online at VirtualInvestorConferences.com Company invites individual and institutional investors, as well as advisors and analysts, to attend online at VirtualInvestorConferences.com
Read More
Belite Bio to Participate in Four Upcoming Investor Conferences
Published: May 12, 2025 by: GlobeNewsWire
Sentiment: Neutral
SAN DIEGO, May 12, 2025 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE), a clinical-stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, today announced that the executive management team will participate in four upcoming investor conferences. Details of the presentations are as follows:
Read More
About Belite Bio, Inc (BLTE)
- IPO Date 2022-04-29
- Website https://belitebio.com
- Industry Biotechnology
- CEO Dr. Yu-Hsin Lin M.B.A., Ph.D.
- Employees 25